Google
XLO 株価分析 — XILIO DEVELOPMENT INC (Healthcare >> Biotechnology)
XLO に関するよくある質問
XLOのPER（株価収益率）は？
XILIO DEVELOPMENT INC（XLO）は現在PER 5.76倍で取引されています。
XLOのROE（自己資本利益率）は？
XILIO DEVELOPMENT INCのROEは-43.15%です。
XLOの配当利回りは？
XILIO DEVELOPMENT INCの配当利回りは0.00%です。
XLOの品質スコア（Quality Score）は？
当社のAIはXLOの総合財務品質を100点中46点と評価しています。収益性・成長性・負債・利益の安定性に基づく評価です。
XLOは今が買い時ですか？
当社AIのタイミングスコアは100点中89点で、テクニカル指標とモメンタムから見た現在価格の相対的な魅力度を示します。
XLOはどのセクターに属しますか？
XILIO DEVELOPMENT INCはHealthcare >> Biotechnologyセクターに分類されます（NASDAQ市場）
XLO AI Analysis Summary
Our AI summary for XLO: XILIO DEVELOPMENT INC (NASDAQ), Healthcare >> Biotechnology sector. The stock currently trades at a P/E of 5.76, ROE of -43.15%, a dividend yield of 0.00%. Its financial Quality Score stands at 46/100 — fundamentals below the market average. The AI Timing Score is 89/100 — multiple technical signals currently support price momentum. All scores are recomputed automatically after each market close from official exchange data. This is systematically generated analysis, not personalized investment advice.
|
USD 9.11
Price
0.03
(0.33%)
Day Change
|
|
|---|
XLO, ファンダメンタルスコアはnot good ( ファンダメンタル = 46) but テクニカルスコアは ...(Sign In to See)...
Loading chart...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
ROEが低い
ROAが低い
平均ROEが低い
ROAの伸びが低い
NPMが低い
NPMの伸びが低い
NPMの伸びが低い
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Momentum indicators aligned on the daily timeframe
In details, quality factors are not quite good , financial health is not quite good , and ability to make profit is not quite good , ...
| Deepscope 分析 |
|
51% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | N/A |
| Magic Formula Rank by ROA |
N/A
|
| Magic Formula Rank by ROE |
N/A
|
| Magic Formula Rank by ROIC |
N/A
|
| Price | 9.11 |
| PBV / Sector |
0.82 / 5.20
GREAT
|
| Earning Per Share | -4.78 |
| PE / Sector |
5.76 / 19.97
GREAT
|
| PEG or PE/Growth / Sector |
0.02 / 1.22
GREAT
|
| Average 1M Daily Value |
0.44 M
GREAT
|
| Average 1W Daily Value |
0.21 M
GREAT
|
| Timing Factors |
|
57% |
| Financial Health |
|
50% |
| ポイントになる統計 |
|
52% |
| 配当 |
|
4% |
| 登録情報 |
| Analyze Date | 2026-08-01 08:00:43 |
| Symbol | XLO |
| Name | XILIO DEVELOPMENT INC |
| Sector | Healthcare >> Biotechnology |
| Market | NASDAQ |
| Listed Shares | 6.58 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 59.70 / 9,903.94 |
| ニュース |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: 828 Winter Street, Waltham, MA, United States, 02451
Phone: 857 524 2466
Website: https://xiliotx.com
Employees: 76
Sector: Healthcare >> Biotechnology
Description: Xilio Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of masked immuno-oncology therapies. The company's pipeline includes XTX501, a bispecific PD-1 / masked IL-2, for patients with metastatic non-small cell lung cancer; Efarindodekin alfa, an investigational, masked IL-12, that is in Phase 2 clinical trial for patients with advanced solid tumors; and Vilastobart, an investigational tumor-activated, Fc-enhanced, high affinity binding anti-CTLA-4 monoclonal antibody. The company was founded in 2016 and is headquartered in Waltham, Massachusetts.
Analyst Ratings & Target Price
ME vs SECTOR Healthcare >> Biotechnology
Click a bubble to view stock details · Bubble size represents market capitalization share
